GLAXOSMITHKLINE PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-0.40% | -.--% |
| 04:26pm | GSK Says Depemokimab Reduced Asthma Attacks in 2 Late-Stage Studies | MT |
| 02:03pm | GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial -- 2nd Update | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3.16TCr 4.02TCr 3.7TCr 3,34500Cr | Sales 2025 * | 3.36TCr 4.27TCr 3.93TCr 3,55200Cr | Capitalization | 7.16TCr 9.1TCr 8.39TCr 7,57500Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 554.5Cr 704.73Cr 649.37Cr 59TCr | Net income 2025 * | 649.4Cr 825.34Cr 760.51Cr 69TCr | EV / Sales 2024 * | 2.65 x |
| Net Debt 2024 * | 1.23TCr 1.56TCr 1.44TCr 1,30000Cr | Net Debt 2025 * | 906.81Cr 1.15TCr 1.06TCr 96TCr | EV / Sales 2025 * | 2.4 x |
| P/E ratio 2024 * |
12.9
x | P/E ratio 2025 * |
11.1
x | Employees | - |
| Yield 2024 * |
3.43% | Yield 2025 * |
3.56% | Free-Float | 94.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on GlaxoSmithKline plc
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 01/10/01 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 01/23/01 |
James Ford
CMP | Compliance Officer | - | 01/95/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 01/23/01 |
Jonathan Symonds
CHM | Chairman | 66 | 01/19/01 |
Hal Barron
BRD | Director/Board Member | 62 | 01/18/01 |
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Sector
Pharmaceuticals
Calendar
21/05/2024
- Berenberg European Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.75
GBP
Average target price
20.32
GBP
Spread / Average Target
+14.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.89% | 71TCr | |
| +32.82% | 58TCr | |
| -3.68% | 36TCr | |
| +19.79% | 33TCr | |
| +5.00% | 29TCr | |
| +16.64% | 24TCr | |
| -4.13% | 21TCr | |
| +10.63% | 21TCr | |
| +8.81% | 17TCr |
- Stock Market
- Equities
- GSK Stock
- GSK Stock